Table 3.
Comparison of 2-year outcomes according to donor HLA matching, disease status, and use of in vivo T cell depletion
| Disease status | Patients group and p value | RI | NRM | LFS | OS | cGVHD | Extensive cGVHD |
|---|---|---|---|---|---|---|---|
| All | 10/10 | 30.1 % [28.2–32.1] | 24.2 % [16.4–32.9] | 45.6 % [43.5–47.7] | 50.6 % [48.5–52.8] | 35.0 % [32.9–37.2] | 17.1 % [15.4–18.9] |
| 9/10 | 32.5 % [28.9–36.3] | 31.6 % [23–40.5] | 35.8 % [32–39.7] | 41.3 % [37.3–45.3] | 35.1 % [31.2–39] | 15.2 % [12.3–18.5] | |
| 8/10 | 24.2 % [16.4–32.9] | 35.5 % [26.6–44.4] | 40.3 % [30.6–50] | 43.5 % [33.6–53.3] | 44.4 % [33.6–54.6] | 26.1 % [16.8–36.4] | |
| p value | 0.152 | 0.002 | 0.0001 | 0.0001 | 0.138 | 0.047 | |
| CR1 | 10/10 | 24.8 % [22.4–27.3] | 22.5 % [11.6–35.7] | 52.6 % [49.7–55.5] | 56.7 % [53.8–59.6] | 37.6 % [34.7–40.5] | 18.1 % [15.8–20.5] |
| 9/10 | 31.6 % [26.3–37.2] | 26.8 % [14.8–40.2] | 41.6 % [35.7–47.5] | 46.1 % [40.1–52.2] | 35.9 % [30–41.9] | 13 % [9.1–17.7] | |
| 8/10 | 17.7 % [8.1–30.2] | 33.3 % [20.4–46.8] | 49% [34.3–63.7] | 50.2 % % [35.2–65.1] | 43.4 % [26.4–59.2] | 22.1 % [9.5–37.9] | |
| p value | 0.010 | 0.136 | 0.005 | 0.005 | 0.641 | 0.107 | |
| ≥CR2 | 10/10 | 32.6 % [28.2–37.1] | 24.1 % [8.7–43.5] | 43.3 % [38.5–48.1] | 50.1 % [45.3–55] | 35 % [30.3–39.7] | 13.9 % [10.6–17.7] |
| 9/10 | 26.3 % [19.5–33.5] | 32.5 % [14.6–51.8] | 41.2 % [33.3–49.2] | 48 % [40–56.1] | 34.7 % [26.8–42.7] | 18.3 % [12.1–25.6] | |
| 8/10 | 22.4 % [7.7–41.7] | 24.6 % [9.1–44.1] | 53 % [31.3–74.7] | 62 % [40.8–83.3] | 65.5 % [39.6–82.4] | 32.2 % [13.8–52.3] | |
| p value | 0.304 | 0.089 | 0.290 | 0.253 | 0.010 | 0.020 | |
| Act. dis. | 10/10 | 39.7 % [35.7–43.7] | 28 % [13.8–44] | 32.3 % [28.4–36.3] | 37.9 % [33.8–42] | 29.4 % [25.5–33.4] | 17.5 % [14–21.5] |
| 9/10 | 38.4 % [31.6–45.3] | 38 % [22.3–53.6] | 23.6 % [17.4–29.7] | 29.1 % [22.5–35.7] | 33.9 % [27.1–40.8] | 16.1 % [10.7–22.5] | |
| 8/10 | 34.3 % [19–50.2] | 45.7 % [29.7–60.4] | 20 % [6.7–33.3] | 22.9 % [8.9–36.8] | 30 % [14.4–47.4] | 26.1 % [10.1–45.5] | |
| p value | 0.902 | 0.062 | 0.107 | 0.139 | 0.587 | 0.578 | |
| In vivo | No | 28.8 % [25.4–32.3] | 27.1 % [23.7–30.7] | 44 % [40.1–48] | 47.7 % [43.7–51.8] | 45 % [40.8–49] | 26.4 % [22.5–30.4] |
| T cell | Yes | 30.7 % [28.8–32.6] | 25.9 % [22.5–29.4] | 43.4 % [41.3–45.5] | 48.8 % [46.7–50.9] | 32.9 % [30.9–34.9] | 14.6 % [13–16.2] |
| Depletion | p value | 0.920 | 0.448 | 0.613 | 0.448 | 1.0483e-05 | 1.337e-09 |
Act. dis. active disease, cGVHD chronic graft-versus-host-disease, CR complete remission, LFS leukemia-free survival, NRM non relapse mortality, OS overall survival, RI relapse incidence